Magnetic Drug Targeting: A Novel Treatment for Intramedullary Spinal Cord Tumors

Pouyan Kheirkhah, Steven Denyer, Abhiraj D. Bhimani, Gregory Arnone, Darian R. Esfahani, Tania Aguilar, Jack Zakrzewski, Indu Venugopal, Nazia Habib, Gary L. Gallia, Andreas Linninger, Fady T. Charbel, Ankit I. Mehta

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Most applications of nanotechnology in cancer have focused on systemic delivery of cytotoxic drugs. Systemic delivery relies on accumulation of nanoparticles in a target tissue through enhanced permeability of leaky vasculature and retention effect of poor lymphatic drainage to increase the therapeutic index. Systemic delivery is limited, however, by toxicity and difficulty crossing natural obstructions, like the blood spine barrier. Magnetic drug targeting (MDT) is a new technique to reach tumors of the central nervous system. Here, we describe a novel therapeutic approach for high-grade intramedullary spinal cord tumors using magnetic nanoparticles (MNP). Using biocompatible compounds to form a superparamagnetic carrier and magnetism as a physical stimulus, MNP-conjugated with doxorubicin were successfully localized to a xenografted tumor in a rat model. This study demonstrates proof-of-concept that MDT may provide a novel technique for effective, concentrated delivery of chemotherapeutic agents to intramedullary spinal cord tumors without the toxicity of systemic administration.

Original languageEnglish (US)
Article number11417
JournalScientific reports
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Spinal Cord Neoplasms
Drug Delivery Systems
Nanoparticles
Central Nervous System Neoplasms
Nanotechnology
Doxorubicin
Drainage
Permeability
Neoplasms
Spine
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • General

Cite this

Kheirkhah, P., Denyer, S., Bhimani, A. D., Arnone, G., Esfahani, D. R., Aguilar, T., ... Mehta, A. I. (2018). Magnetic Drug Targeting: A Novel Treatment for Intramedullary Spinal Cord Tumors. Scientific reports, 8(1), [11417]. https://doi.org/10.1038/s41598-018-29736-5
Kheirkhah, Pouyan ; Denyer, Steven ; Bhimani, Abhiraj D. ; Arnone, Gregory ; Esfahani, Darian R. ; Aguilar, Tania ; Zakrzewski, Jack ; Venugopal, Indu ; Habib, Nazia ; Gallia, Gary L. ; Linninger, Andreas ; Charbel, Fady T. ; Mehta, Ankit I. / Magnetic Drug Targeting : A Novel Treatment for Intramedullary Spinal Cord Tumors. In: Scientific reports. 2018 ; Vol. 8, No. 1.
@article{efe02a4a75b54a1a9909266211b800c2,
title = "Magnetic Drug Targeting: A Novel Treatment for Intramedullary Spinal Cord Tumors",
abstract = "Most applications of nanotechnology in cancer have focused on systemic delivery of cytotoxic drugs. Systemic delivery relies on accumulation of nanoparticles in a target tissue through enhanced permeability of leaky vasculature and retention effect of poor lymphatic drainage to increase the therapeutic index. Systemic delivery is limited, however, by toxicity and difficulty crossing natural obstructions, like the blood spine barrier. Magnetic drug targeting (MDT) is a new technique to reach tumors of the central nervous system. Here, we describe a novel therapeutic approach for high-grade intramedullary spinal cord tumors using magnetic nanoparticles (MNP). Using biocompatible compounds to form a superparamagnetic carrier and magnetism as a physical stimulus, MNP-conjugated with doxorubicin were successfully localized to a xenografted tumor in a rat model. This study demonstrates proof-of-concept that MDT may provide a novel technique for effective, concentrated delivery of chemotherapeutic agents to intramedullary spinal cord tumors without the toxicity of systemic administration.",
author = "Pouyan Kheirkhah and Steven Denyer and Bhimani, {Abhiraj D.} and Gregory Arnone and Esfahani, {Darian R.} and Tania Aguilar and Jack Zakrzewski and Indu Venugopal and Nazia Habib and Gallia, {Gary L.} and Andreas Linninger and Charbel, {Fady T.} and Mehta, {Ankit I.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-29736-5",
language = "English (US)",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Kheirkhah, P, Denyer, S, Bhimani, AD, Arnone, G, Esfahani, DR, Aguilar, T, Zakrzewski, J, Venugopal, I, Habib, N, Gallia, GL, Linninger, A, Charbel, FT & Mehta, AI 2018, 'Magnetic Drug Targeting: A Novel Treatment for Intramedullary Spinal Cord Tumors', Scientific reports, vol. 8, no. 1, 11417. https://doi.org/10.1038/s41598-018-29736-5

Magnetic Drug Targeting : A Novel Treatment for Intramedullary Spinal Cord Tumors. / Kheirkhah, Pouyan; Denyer, Steven; Bhimani, Abhiraj D.; Arnone, Gregory; Esfahani, Darian R.; Aguilar, Tania; Zakrzewski, Jack; Venugopal, Indu; Habib, Nazia; Gallia, Gary L.; Linninger, Andreas; Charbel, Fady T.; Mehta, Ankit I.

In: Scientific reports, Vol. 8, No. 1, 11417, 01.12.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Magnetic Drug Targeting

T2 - A Novel Treatment for Intramedullary Spinal Cord Tumors

AU - Kheirkhah, Pouyan

AU - Denyer, Steven

AU - Bhimani, Abhiraj D.

AU - Arnone, Gregory

AU - Esfahani, Darian R.

AU - Aguilar, Tania

AU - Zakrzewski, Jack

AU - Venugopal, Indu

AU - Habib, Nazia

AU - Gallia, Gary L.

AU - Linninger, Andreas

AU - Charbel, Fady T.

AU - Mehta, Ankit I.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Most applications of nanotechnology in cancer have focused on systemic delivery of cytotoxic drugs. Systemic delivery relies on accumulation of nanoparticles in a target tissue through enhanced permeability of leaky vasculature and retention effect of poor lymphatic drainage to increase the therapeutic index. Systemic delivery is limited, however, by toxicity and difficulty crossing natural obstructions, like the blood spine barrier. Magnetic drug targeting (MDT) is a new technique to reach tumors of the central nervous system. Here, we describe a novel therapeutic approach for high-grade intramedullary spinal cord tumors using magnetic nanoparticles (MNP). Using biocompatible compounds to form a superparamagnetic carrier and magnetism as a physical stimulus, MNP-conjugated with doxorubicin were successfully localized to a xenografted tumor in a rat model. This study demonstrates proof-of-concept that MDT may provide a novel technique for effective, concentrated delivery of chemotherapeutic agents to intramedullary spinal cord tumors without the toxicity of systemic administration.

AB - Most applications of nanotechnology in cancer have focused on systemic delivery of cytotoxic drugs. Systemic delivery relies on accumulation of nanoparticles in a target tissue through enhanced permeability of leaky vasculature and retention effect of poor lymphatic drainage to increase the therapeutic index. Systemic delivery is limited, however, by toxicity and difficulty crossing natural obstructions, like the blood spine barrier. Magnetic drug targeting (MDT) is a new technique to reach tumors of the central nervous system. Here, we describe a novel therapeutic approach for high-grade intramedullary spinal cord tumors using magnetic nanoparticles (MNP). Using biocompatible compounds to form a superparamagnetic carrier and magnetism as a physical stimulus, MNP-conjugated with doxorubicin were successfully localized to a xenografted tumor in a rat model. This study demonstrates proof-of-concept that MDT may provide a novel technique for effective, concentrated delivery of chemotherapeutic agents to intramedullary spinal cord tumors without the toxicity of systemic administration.

UR - http://www.scopus.com/inward/record.url?scp=85050800113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050800113&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-29736-5

DO - 10.1038/s41598-018-29736-5

M3 - Article

C2 - 30061692

AN - SCOPUS:85050800113

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 11417

ER -